{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:44:57Z","timestamp":1760237097384,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Sciences Italy","award":["FP14MO"],"award-info":[{"award-number":["FP14MO"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>We prospectively evaluated the frequency of natural resistance-associated substitutions (RASs) in the NS3 and NS5A regions according to different HCV genotypes and their possible effect on treatment outcome in HIV-1\/HCV patients treated with direct-acting antivirals (DAAs). Baseline RASs in the NS3 and NS5A domains were investigated in 62 HIV-1\/HCV patients treated with DAAs: 23 patients harbored HCV-GT1a, 26 harbored GT3a, and 13 harbored GT4d. A higher occurrence of RASs was found in the NS3 domain within GT1a (13\/23) than GT3a (0\/26) or GT4d (2\/13). With regard to treatment outcome, NS3 RASs were detected in 14\/56 patients with sustained virological response (SVR) and in 1\/6 non-responder (NR) patients. Occurrence of RASs of NS5A domain was lower in SVR (4\/56, had RASs) than in NR (3\/6, had RASs). Evaluation of RASs at baseline instead of at virological failure, especially in the NS5A domain, could positively influence the choice of new DAA combinations for the treatment of HIV-1\/HCV patients.<\/jats:p>","DOI":"10.3390\/v12030269","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T03:13:28Z","timestamp":1583205208000},"page":"269","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1\/HCV Coinfected Patients and Association with Treatment Outcome"],"prefix":"10.3390","volume":"12","author":[{"given":"Sabrina","family":"Bagaglio","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, IRCCS, Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Hasson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, IRCCS, Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Peano","sequence":"additional","affiliation":[{"name":"Ordine dei Medici della Valle d\u2019Aosta, 11100 Aosta, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Vercesi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, IRCCS, Ospedale San Raffaele, 20132 Milan, Italy"},{"name":"Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Messina","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, IRCCS, Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Galli","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, IRCCS, Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5271-9138","authenticated-orcid":false,"given":"Caterina","family":"Uberti-Foppa","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-5376","authenticated-orcid":false,"given":"Giulia","family":"Morsica","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, IRCCS, Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist. Updat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: In vitro and in vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/AAC.00763-16","article-title":"Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein","volume":"60","author":"Lawitz","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Krishnan, P., Schnell, G., Tripathi, R., Beyer, J., Reisch, T., Dekhtyar, T., Irvin, M., Xie, W., Fu, B., and Burroughs, M. (2018). Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.02217-17"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/jmv.24971","article-title":"Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients","volume":"90","author":"Carrasco","year":"2018","journal-title":"J. Med. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3851\/IMP2871","article-title":"Baseline drug resistance mutations are detectable in HCV genes NS3 and NS5A but not NS5B in acute and chronic HIV-coinfected patients","volume":"20","author":"McCormick","year":"2015","journal-title":"Antivir. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10096-019-03488-0","article-title":"Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection","volume":"38","author":"Bisbal","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_9","unstructured":"(2019, November 27). Italian Guidelines (SIMIT). Available online: http:\/\/www.simit.org\/IT\/formazione\/linee-guida.xhtml."},{"key":"ref_10","unstructured":"(2019, November 27). International Guidelines (EACS). Available online: https:\/\/www.eacsociety.org\/files\/2019_guidelines-10.0_final.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: State of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20310","DOI":"10.1038\/srep20310","article-title":"Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): Mining the GenBank HCV genome data","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8988","DOI":"10.1038\/s41598-018-26862-y","article-title":"HCV Virology Italian Resistance Network (VIRONET-C). Prevalence of single and multiple natural NS3, NS5A and NS5B resistance-associated substitutions in hepatitis C virus genotypes 1-4 in Italy","volume":"8","author":"Bertoli","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"19741","DOI":"10.7448\/IAS.17.4.19741","article-title":"Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV\/HCV co-infected patients in a Berlin laboratory","volume":"17","author":"Ehret","year":"2014","journal-title":"J. Int. Aids Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3851\/IMP2964","article-title":"Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals","volume":"20","author":"Nguyen","year":"2015","journal-title":"Antivir. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"ofv043","DOI":"10.1093\/ofid\/ofv043","article-title":"Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors","volume":"2","author":"Sierra","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s15010-016-0937-4","article-title":"HCV NS3 naturally occurring variants in HIV\/HCV coinfected DAA-na\u00efve patients: Consideration for HCV genotyping resistance testing","volume":"44","author":"Ruggiero","year":"2016","journal-title":"Infection"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","article-title":"Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses","volume":"67","author":"Welzel","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1080\/17425255.2016.1209484","article-title":"Hepatitis C virus resistance to the new direct-acting antivirals","volume":"12","author":"Esposito","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/jvh.12615","article-title":"InC3 Study Group. Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents","volume":"24","author":"Eltahla","year":"2017","journal-title":"J. Viral. Hepat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/infdis\/jiv379","article-title":"NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 Infection","volume":"213","author":"Zhou","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/infdis\/jir021","article-title":"Two years\u2019 persistence of naturally present substitution R155K within hepatitis C virus NS3 protease in the absence of protease inhibitor-based therapy","volume":"203","author":"Colson","year":"2011","journal-title":"J. Infect. Dis."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/3\/269\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:02:32Z","timestamp":1760173352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/3\/269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,28]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["v12030269"],"URL":"https:\/\/doi.org\/10.3390\/v12030269","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2020,2,28]]}}}